Full Text View
Tabular View
No Study Results Posted
Related Studies
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation (ECLIPSE)
This study has been completed.
Study NCT01208961   Information provided by Omthera Pharmaceuticals, Inc

First Received on September 23, 2010.   Last Updated on January 5, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Severe Hypertriglyceridemia
Additional conditions recognized in this trial
Hypertriglyceridemia
More general conditions related to this trial
Dyslipidemias
Hyperlipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
Epanova (4 g) and Lovaza (4 g)
Lovaza (4 g) and Epanova (4 g)
Sponsors listed in this trial
Omthera Pharmaceuticals, Inc
Radiant Research


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services